ArticleAntimicrobial agents and chemotherapy2005
Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 51 citations in OpenAlex.
- Adoption of an in-silico analysis approach to assess the functional and structural impacts of rpoB-encoded protein mutations on Chlamydia pneumoniae sensitivity to antibiotics.BMC microbiology · 2025Article
- Insights into Chlamydia Development and Host Cells Response.Microorganisms · 2024Review
- Oh my gut! Is the microbial origin of neurodegenerative diseases real?Infection and immunity · 2023Review
- Review
- An in silico analysis of rpoB mutations to affect Chlamydia trachomatis sensitivity to rifamycin.Journal, genetic engineering & biotechnology · 2022Article
- An overview of genes and mutations associated with Chlamydiae species' resistance to antibiotics.Annals of clinical microbiology and antimicrobials · 2021Review
- Neuroprotective effects of some epigenetic modifying drugs' on Chlamydia pneumoniae-induced neuroinflammation: A novel model.PloS one · 2021Article
- Generation of Tetracycline and Rifamycin ResistantFrontiers in microbiology · 2021Article
- Water-filtered infrared a irradiation in combination with visible light inhibits acute chlamydial infection.PloS one · 2014Article
- Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.Antimicrobial agents and chemotherapy · 2012Article
- Genomic stability of genotyping markers in Chlamydia trachomatis.Frontiers in cellular and infection microbiology · 2012Article
- Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles.Biomaterials · 2011Article
- Generation of targeted Chlamydia trachomatis null mutants.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Antibiotic resistance in Chlamydiae.Future microbiology · 2010Review
- A novel inhibitor of Chlamydophila pneumoniae protein kinase D (PknD) inhibits phosphorylation of CdsD and suppresses bacterial replication.BMC microbiology · 2009Article
- In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2006Article
- In vivo and in vitro studies of Chlamydia trachomatis TrpR:DNA interactions.Molecular microbiology · 2006Article
- Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection.Antimicrobial agents and chemotherapy · 2006Article
- Combating Tuberculosis Infection: A Forbidding Challenge.Indian journal of pharmaceutical sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although rifamycins have excellent activity against Chlamydophila pneumoniae and Chlamydia trachomatis in vitro, concerns about the possible development of resistance during therapy have discouraged their use for treatment of chlamydial infections. Rifalazil, a new semisynthetic rifamycin with a long half-life, is the most active antimicrobial against C. pneumoniae and C. trachomatis in vitro, indicating its potential for treatment of acute and chronic C. pneumoniae and C. trachomatis infections. We investigated the effect of serial passage of two C. pneumoniae isolates and two serotypes of C. trachomatis in subinhibitory concentrations of rifalazil and rifampin on the development of phenotypic and genotypic resistance. C. trachomatis developed resistance to both antimicrobials within six passages, with higher level resistance to rifampin (128 to 256 microg/ml) and lower level resistance to rifalazil (0.5 to 1 microg/ml). C. pneumoniae TW-183 developed only low-level resistance to rifampin (0.25 microg/ml) and rifalazil (0.016 microg/ml) after 12 passages. C. pneumoniae CWL-029 failed to develop resistance to either drug. Two unique mutations emerged in the rpoB gene of rifampin (L456I) and rifalazil (D461E)-resistant C. pneumoniae TW-183. A single mutation (H471Y) was detected in both rifampin- and rifalazil-resistant C. trachomatis UW-3/Cx/D, and a unique mutation (V136F) was found in rifalazil-resistant BU-434/L(2). No mutations were detected in the entire rpoB gene of rifampin-resistant BU-434/L(2). This is the first description of antibiotic resistance-associated mutations in C. pneumoniae and of rifampin resistance in C. trachomatis not associated with mutations in the rpoB gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.